Frequency Therapeutics, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- David L. Lucchino
- Full Time Employees
- 46
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 75 Hayden Avenue Lexington MA United States of America 02421
- IPO Date
- Oct 3, 2019
- CIK
- 0001703647
- Website
- frequencytx.com
- Similar Companies
- Business
- Frequency Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapeutics that activate a person's innate regenerative potential through progenitor cell activation to restore lost function. The company's primary product pipeline includes FX-322, a proprietary small-molecule drug candidate designed to regenerate auditory sensory hair cells in the cochlea, targeting the treatment of sensorineural hearing loss. In addition to hearing loss, Frequency Therapeutics is advancing programs to develop disease-modifying therapies for degenerative conditions such as multiple sclerosis, muscle diseases, gastrointestinal disorders, skin conditions, and bone diseases. Its technology platform centers on utilizing small molecules to stimulate progenitor cells to create functional tissue. The company operates mainly in the United States and has established collaboration and licensing agreements with partners including Astellas Pharma, Massachusetts Eye and Ear, the Massachusetts Institute of Technology, and The Scripps Research Institute. Frequency Therapeutics was founded in 2014 and is headquartered in Lexington, Massachusetts. In late 2023, Frequency Therapeutics merged with Korro Bio, an RNA editing therapeutics company, in an all-stock reverse merger transaction, resulting in a strategic shift towards expanding therapeutic modalities into RNA-based drug development. This merger enabled the combined entity to leverage Korro Bio’s portfolio while retaining Frequency’s regenerative medicine programs. The transaction was supported by a concurrent $117 million financing round, providing the combined company approximately $170 million in pro-forma cash and marketable securities to fund ongoing clinical development through 2026. The company has discontinued development of its remyelination program for multiple sclerosis as part of its strategic realignment. This merger and related financing are among the most significant recent operational and financial developments for Frequency Therapeutics. Frequency Therapeutics operates within the biotechnology and pharmaceutical sectors, targeting patients with degenerative diseases and hearing loss. Its current business strategy emphasizes advancing clinical programs using its progenitor cell activation technology along with integrating RNA-based therapeutic approaches from Korro Bio to enhance its pipeline diversity and long-term growth potential. Overall, Frequency Therapeutics represents a biotechnology firm focused on pioneering regenerative medicine treatments with a specialized proprietary technology and has recently restructured through merger activity to broaden its scientific capabilities and financial resources in the evolving biotech landscape.
Frequency Exchange Corp. Appoints Gail Edgell To Advisory Board
Frequency Exchange Appoints Michael MOE To Advisory Board
NIKKI's Efficacy in Overcoming Lyme Disease to be Presented at 2024 Leap into Health Conference
UPDATE: Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million
Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million
FREQUENCY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Frequency Therapeutics, Inc. - FREQ
Frequency Therapeutics Provides Business Updates and Second Quarter 2023 Financial Results
FREQUENCY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Frequency Therapeutics, Inc. - FREQ
Frequency (FREQ) Up 77% on Merger Deal With Korro Bio
FREQ Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Frequency Therapeutics, Inc. Is Fair to Shareholders
Why Is Frequency Therapeutics (FREQ) Stock Up 44% Today?
Korro Bio and Frequency Therapeutics Announce Merger Agreement
Frequency Therapeutics Provides Business Updates and First Quarter 2023 Financial Results
Frequency Therapeutics Provides Business Updates and Fourth Quarter and Full Year 2022 Financial Results
Frequency Therapeutics to Participate at Upcoming March Investor Conferences
Small Animal Imaging In Vivo Market is Anticipated to Reach a Value of USD 6.1 Billion by Growing at a CAGR of 8.89% During 2022-2028; Expanding Healthcare Sector and Rising Clinical Research to Elevate Market Growth
FREQ Stock: 80.54% Plummet Explanation
Frequency Therapeutics Announces Topline Results for its Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss
Frequency Therapeutics Announces Formation of Clinical Advisory Board for Remyelination in Multiple Sclerosis Program
Frequency Therapeutics Announces First Patient Dosed in Phase 1b Study of FX-345, the Company's Second Therapeutic Candidate for Sensorineural Hearing Loss